A Novel Immunotherapy PD-1 Antiboty to Suppress Recurrence of HCC Combined With PVTT After Hepatic Resection
Status:
Unknown status
Trial end date:
2020-01-31
Target enrollment:
Participant gender:
Summary
Hepatic resection is the most effective curative treatment for resectable HCC, whereas
frequent recurrence usually impaired the efficacy of hepatic resection and contributed poor
survivals. PVTT has been certified as an independent risk of early recurrence.
Although TACE has been used to decrease the intraheptic recurrence. However, the intraheptic
recurrence rate remains high and meanwhile it is uncapable to suppress extrahepatic
recurrence. In addition, systematic therapy the small molecular target antiangiogenesis
medicine sorafenib were used to prevent recurrence. Unfortunately, the STORM trial shows that
postoperative antiangiogenesis therapy was failed to suppress recurrence and prolong survival
period for HCC patients. Thus, novel effective systematic therapy to suppress postoperative
recurrence is in urgent need.
At present, the PD-1 antibody has presented a promising and safe therapeutic result of
unresectable HCC and provided good survival benefit for advanced HCC patients. Consistent
with this, we proposed a hypothesis that a novel immunetherapy using the PD-1 antibody could
suppress postoperative recurrence and prolong HCC patients survival period effectively.